CPTU
Stockholm, Sweden
NCT Number: NCT01704638
The investigators will compare plasma kinetics of two marker drugs in individuals with different genetic variations in the MDR1-gene. The hypothesis is that one group will have higher exposure than the other.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1
Stockholm, Sweden
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 2 days for fluvoxamine and 2 days for digoxin. Washout period of at least 1 week between the both parts. Total study time maximum 4 weeks.
The participants are administered a single dose of fluvoxamine or digoxin. Plasma kinetics of fluvoxamine are followed for 36 hours. Plasma kinetics of digoxin are followed for 48 hours. There is a washout period between the both parts.
Karolinska Institutet
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00044174
Behavior, Behavioral Symptoms
Bethesda, Maryland, United States
View Trial DetailsNCT05321628
Anxiety Disorders, Behavior
Stockholm, Huddinge, Sweden
View Trial DetailsNCT06993662
Anxiety, Anxiety Disorders
Athens, Greece
View Trial DetailsNCT03851380
Behavior, Behavioral Symptoms
Palo Alto, California, United States
View Trial Details